Skip to main content
Clinical Trials/EUCTR2012-005265-13-IT
EUCTR2012-005265-13-IT
Active, not recruiting
Phase 1

Efficacy of intralesional infusion of local anesthetics in patients undergoing major abdominal surgery: a randomized double-blind trial. - PT-SM-13-YR

Fondazione IRCCS Policlinico San Matteo0 sites120 target enrollmentMarch 22, 2013

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Patients undergoning major abdominal surgery requiring postoperative analgesic therapy, not hospitalized in intensive care and not using drugs by neuraxial analgesia
Sponsor
Fondazione IRCCS Policlinico San Matteo
Enrollment
120
Status
Active, not recruiting
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 22, 2013
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- Male and females 18\-75 years old scheduled to use PCA with morphine for postoperative pain control
  • \- HIV\-negative
  • \- Classification American Society of Anesthesiologists (ASA) I: without systemic disease
  • \- Classification ASA II or III (moderate systemic disease or severe systemic disease that limits activity without disability)
  • \- Scheduled for major abdominal and urologic surgery (no emergency surgery)
  • \- Signed informed consent
  • \- No severe hepatic or renal impairment (cholinesterase \<3000 mU / ml, total bilirubiemia \<2 mg / dl and creatinine \<1\.2 mg / dl)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes

Exclusion Criteria

  • \- regular use of opioid analgesics;
  • \- History of abuse of drugs and / or alcohol;
  • \- Postoperative hospitalization in intensive care with sedation and / or mechanical ventilation;
  • \- severe renal impairment (creatinine\> 2 g / dl, creatinine clearance \<30 ml / h) and / or hepatic impairment (cholinesterase \<2000 IU);
  • \- Cardiac disorders (arrhythmias, heart failure);
  • \- Neurological disorders (epilepsy);
  • \- Cognitive disorders, mental retardation, psychiatric disorders;
  • \- Changes in the normal coagulation or coagulopathy (INR\> 2, PTT\> 44 sec);
  • \- Platelet count less than 100\.000/mm3;
  • \- BMI\> 30;

Outcomes

Primary Outcomes

Not specified

Similar Trials